Skip to main content
. 2019 Dec 4;6:284. doi: 10.3389/fmed.2019.00284

Figure 1.

Figure 1

Treatment of advanced metastatic non-small cell lung cancer (NSCLC)- according to ESMO guidelines (10). ADC, adenocarcinoma; cfDNA, circulating free DNA; ChT, chemotherapy; NOS, not otherwise specified; PD-L1, programmed death ligand; SQCC, squamous cell carcinoma; TMB, tumor mutational burden; TKI, tyrosine kinase inhibitors; TPS, tumor proportion score.